Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener Medizinische Wochenschrift
Erschienen in:

01.11.2013 | case report

Triple-negative breast cancer possibly transforming into malignant melanoma due to targeted therapy? A case report and review of literature

verfasst von: Birgit Aigner, Prof. Dr. med. Sabine Gisela Plötz, Prof. Dr. med. Gerhard Schaller

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 21-22/2013

Einloggen, um Zugang zu erhalten

Summary

Background

Triple-negative breast cancer (TNBC) is characterized by lacking expression of estrogen receptor and progesterone receptor as well as absence of human epidermal growth factor receptor 2 overexpression and is an aggressive clinical phenotype.

Patients and methods

We report the case of a 33-year-old woman who has been treated using a targeted approach for TNBC and developed a malignant melanoma metastasis without any primary.

Results and conclusion

Using targeted therapies, tumors can be treated much more effectively, but up to now, we do not know much about potential adverse reactions. Due to the targeted therapy, tumors may be pressurized for transformation. We call for further investigations to rule out the potential risks of targeted therapy in TNBC. This is the first report of a potential transforming of one tumor entity to another by a targeted therapy.
Vorheriger Artikel Aktuelle Anforderungen an die Diagnostik bei chronisch myeloischer Leukämie
Nächster Artikel Anorectal malignant melanoma in a hemorrhoidal nodule: a diagnostic and therapeutic problem
Literatur
1.
Berrada N, Delaloge S, Andre F. Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization? Ann Oncol. 2010;21(7):vii30–5.PubMed
2.
Pal SK, Childs BH, Pegram M. Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat. 2011;125:627–36.PubMedCrossRef
3.
Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes and survival in the Carolina breast cancer study. JAMA. 2006;295:2492–502.PubMedCrossRef
4.
Alvarez RH, Valero V, Hortobagyi GN. Emerging targeted therapies for breast cancer. J Clin Oncol. 2010;28:3366–79.PubMedCrossRef
5.
Andre F, Job B, Dessen P, et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res. 2009;14:441–51.CrossRef
6.
Bühler H, Schaller G. Transfection of keratin 18 gene in human breast cancer cells causes induction of adhesion proteins and dramatic regression of malignancy in vitro and in vivo. Mol Cancer Res. 2005;3(7):356–71.CrossRef
7.
Sikov WM, Dizon DS, Strenger R, et al. Frequent pathological complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study. J Clin Oncol. 2009;27(28):4693–700.PubMedCrossRef
8.
Loesch D, Robert N, Asmar L, et al. Phase II multicentre trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. J Clin Oncol. 2002;20(18):3857–64.PubMedCrossRef
9.
Chang HR, Glaspy J, Allison MA, et al. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer. 2010;116:4227–37.PubMedCrossRef
10.
Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL. Independent review of E2100: a phase III trail of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2009;27:4966–72.PubMedCrossRef
11.
Aprile G, Mazzer M, Moroso S, Puglisi F. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer. Anticancer Drugs. 2009;20:217–29.PubMedCrossRef
12.
Goggins W, Gap W, Tsao H. Association between female breast cancer and cutaneous melanoma. Int J Cancer. 2004;111:792–4.PubMedCrossRef
13.
Kirova YM, De Rycke Y, Gambotti L, Pierga J-Y, Asselain B, Fourquet A. Second malignancies after breast cancer: the impact of different treatment modalities. Br J Cancer. 2008;98:870–4.PubMedCrossRef
14.
Mellemkjaer L, Friis S, Olsen JH, et al. Risk of second cancer among women with breast cancer. Int J Cancer. 2006;118:2285–92.PubMedCrossRef
15.
Weitzen R, Harari G, Achiron A, Catane R, Mandel M. Melanoma risk in women with previous breast cancer. J Clin Oncol. 2004;22:7553.
16.
Faehling M, Eckert R, Kamp T, et al. EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: a case-control study of overall survival. Lung Cancer. 2013;80(3):306–12.PubMedCrossRef
Metadaten
Titel
Triple-negative breast cancer possibly transforming into malignant melanoma due to targeted therapy? A case report and review of literature
verfasst von
Birgit Aigner
Prof. Dr. med. Sabine Gisela Plötz
Prof. Dr. med. Gerhard Schaller
Publikationsdatum
01.11.2013
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 21-22/2013
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-013-0242-0

Weitere Artikel der Ausgabe 21-22/2013

Buchbesprechung

  • buchbesprechung

Unclassified cardiomyopathies in neuromuscular disorders

  • review

Cyclic vomiting syndrome in adults

  • case report

Aktuelle Anforderungen an die Diagnostik bei chronisch myeloischer Leukämie

  • review

Anorectal malignant melanoma in a hemorrhoidal nodule: a diagnostic and therapeutic problem

  • case report